Osteoporosis consists in a disorder in which the bones become increasingly porous, brittle, and subject to fracture, owing to loss of calcium and other mineral components, sometimes resulting in pain, decreased height, and skeletal deformities
Current drugs have a limited efficacy and an adverse effect.
Studies have shown the evidence of the relationship between intestinal hormones and bone health. The variation in food intake is associated with significant changes in bone markers reabsorption, being intestinal and pancreatic peptides the most important effectors of the acute response that occurs in bone metabolism regard to food intake.
The Spanish research group has developed a drug to obtain useful data for the screening, diagnosis, prognosis and/or monitoring osteoporosis.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parties to use the method.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations.